China NMPA Product Recall - Drug infusion system

On January 5, 2021, Medtronic (Shanghai) Management Co., Ltd. initiated a voluntary Class III recall of its drug infusion systems (Registration Certificate No.: 20173545069). This action was taken under the oversight of the National Medical Products Administration (NMPA), specifically reported by the Shanghai Municipal Drug Administration. The recall stems from eight post-market reports received over a two-year period, detailing instances where patients were prematurely discharged after infusion therapy was halted without the pump programming being fully completed. While the programmable device's interface did display warnings indicating incomplete programming, healthcare professionals unfortunately failed to notice or act upon these critical alerts. This situation highlights a significant user interface interaction challenge rather than a fundamental device malfunction, as the warning mechanism itself was operational. In response to these incidents, Medtronic is undertaking proactive measures. The company will issue comprehensive notifications to all customers utilizing the affected products. These communications will specifically highlight and reinforce the existing warnings and incorporate clear images of the programmable interface when programming is incomplete. The primary objective of these required actions is to significantly enhance customer awareness regarding the proper completion of programming steps and to mitigate the risk of future operational errors that could impact patient care. This voluntary recall underscores the importance of both device design and user vigilance in medical settings.